WHO’s director general described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.

Illimis has completed a Series B funding round, securing $42m for the development of its GAIA-based Alzheimer's disease therapeutics.

Ultragenyx Pharmaceutical has received a complete response letter (CRL) from the FDA concerning its BLA for UX111 (ABO-102).

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

The FDA has accepted MSD’s doravirine/islatravir new drug application (NDA) for review to treat adults with virologically suppressed HIV-1.

With clinical trials under pressure, industry leaders say it’s time for reform, digital transformation, and more patient-centric models.

IGI Therapeutics has signed an exclusive licensing agreement with AbbVie, for ISB 2001 to treat cancer and autoimmune diseases.

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

Despite the threat of a 200% tariff, most pharma stocks remained stable. US President Donald Trump’s 200% tariff threat on the pharmaceutical industry is a “shock” that will reverberate through global ...

In a recent webinar, industry experts explain how real-world data and patient-centric support can shape regulatory success ...

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for newborns and young infants. Known as ...